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ABSTRACT 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not the use 
of varenicline for smoking-cessation therapy creates or increases depression in patients without 
existing depressive illness. 
 
STUDY DESIGN: Review of two randomized controlled trials published in 2011 and one 
observational cohort study published in 2009, all English language. 
 
DATA SOURCES: Two randomized, double-blind, controlled clinical trials comparing 
varenicline to placebo in smoking cessation, and one observational cohort study comparing 
varenicline use within subjects. All articles were found using PubMed and EBSCO.  
 
OUTCOMES MEASURED: Changes in depression was evaluated using the Montgomery-
Åsberg Depression Rating Scale (MADRS), and adverse events were recorded and classified into 
depression-related according to the Medical Dictionary for Regulatory Activities version 12 and, 
in the observational cohort study, the British Drug Safety Research Unit standards. 
 
RESULTS: Bollinger et al. and Garza et al. demonstrated a present but nonsignificant increase in 
depressive adverse events associated with varenicline use.  Garza et al. reported a similarly small 
and nonsignificant worsening in MADRS score in the varenicline arm.  Kasliwal et al. reported a 
nonsignificant change in depressive adverse events. 
 
CONCLUSIONS: Results of the three studies show that there is inconclusive evidence regarding 
a link between varenicline and new-onset depression in smoking cessation.  None of the studies 
demonstrated any significant relationship between varenicline and depression or depressive 
adverse events, but limitations in study design prevent the results from convincingly addressing 
such a relationship.  The results encourage further studies designed both to assess varenicline’s 
relationship with depression and to account for the varenicline’s higher quit rate as a possible 
source of depressive changes.  
 
KEY WORDS: varenicline, depression, randomized, adverse
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INTRODUCTION 
 Smoking is a prominent risk factor for a wide variety of pathologies, and remains a 
common component of patient social histories.  The addictive nature of smoking renders 
smoking cessation difficult for most patients, and drug-assisted methods are increasingly being 
considered in the quitting process.5  One such drug, varenicline, can be effective but remains 
controversial due to concerns of depression-related adverse effects.13 
 An estimated 45.3 million U.S. adults smoke cigarettes—about 19.3% of the U.S. 
population greater than 18 years of age.6  While smoking-related health care visits have proven 
too numerous to track reliably, smoking-attributable deaths in the U.S. average approximately 
443,000 per year.5  Because of cigarette smoking’s combination of systemic effects and addictive 
pharmacodynamics, annual health-related economic losses in the U.S. are estimated at $193 
billion—more than 10% of total U.S. annual healthcare expenditures.5  Cost estimates are not 
limited to the macro-scale; one longitudinal analysis considered health-care costs, opportunity 
costs and other assorted factors, and estimated an effective per-pack cost to regular smokers of 
almost $40.15  Smoking cessation with varenicline typically costs between $50 and $192 per 
month, with a typical regimen lasting 3 months.7 
 Smoking addiction has been principally traced to the agonistic effects of nicotine on 
nicotinic acetylcholine receptors, which preferentially release dopamine in the central nervous 
system.  As with other addictive dopaminergic compounds (e.g., cocaine, opiates), this reinforces 
addictive behavior and, with dependence, causes withdrawal symptoms when absent.  Recent 
studies have demonstrated evidence of addiction within only weeks of smoking and, in some 
individuals, within only days.8  Withdrawal symptoms stem from nicotine-induced down-
regulation of dopamine and other neurotransmitters, the deficiency of which can cause headache, 
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anxiety, nausea, dysphoria, depression, paresthesias, and intense cravings.  Beyond its neurologic 
effects, cigarette smoking produces profound deleterious changes elsewhere in the body.  
Carcinogenic effects increase rates of lung cancer, along with cancers of the mouth, larynx, 
pharynx, sinuses, esophagus, liver, pancreas, stomach, kidney, bladder, cervix, bowel, and blood.  
Increases in blood viscosity exacerbate ischemic disease.  Breathing allergies are aggravated, and 
smoking can create or worsen obstructive pulmonary disease. 
 Smoking cessation is a significant and difficult process; the majority of smokers indicate 
they would like to quit, about 36% make an annual attempt to quit, and only 3% successfully 
remain smoking-abstinent after six months.13  Traditional strategies for smoking-cessation have 
generally been unassisted: self-imposed abrupt cessation (“cold turkey”) or gradual cessation 
(“weaning”), or assisted: group therapy, psychosocial therapy, or long-term counseling.  More 
recently developed assisted strategies utilize pharmacotherapy, with the hope of improving on 
the poor long-term quit rates of traditional efforts.  Drug-assisted strategies fall into two 
categories: nicotine-replacement therapy (NRT), and psychoactive therapy.  NRT has shown 
some efficacy coupled with a low adverse-event profile, but its long-term efficacy has proven 
questionable.1  The two mainstays of psychoactive therapy are bupropion SR—an atypical 
antidepressant—and varenicline—a nicotine receptor partial agonist.  Both medications have 
demonstrated improved efficacy over both traditional methods and NRT, but epidemiological 
surveillance and case reports have raised concerns regarding neuropsychiatric adverse events; the 
U.S. Food and Drug Administration (FDA) has issued a Black Box Warning of neuropsychiatric 
symptoms and suicidality for both drugs.3,13  Varenicline has been shown to have the highest 
efficacy of smoking cessation options, but depression and suicide may be very serious side 
effects of the drug—especially in patients with no prior history of depressive illness, who may 
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suffer dangerous depressive symptoms before they are identified by the patient or healthcare 
provider.3,4  This selective evidence-based medicine review evaluated two randomized, placebo-
controlled, double-blind studies and one observational cohort study to examine the depressive 
adverse effects of varenicline in smoking cessation. 
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not the use of 
varenicline for smoking-cessation therapy creates or increases depression in patients without 
existing depressive illness.  
METHODS 
 The population chosen adult smokers ≥ 18 years of age, with the RCTs further selecting 
subjects that smoked an average of 10+ cigarettes a day during the previous year, with no period 
of abstinence greater than 3 months.  The intervention studied in the RCTs was varenicline in its 
standardized dosing schedule: 0.5 mg QD for 3 days, followed with 0.5 mg BID for 4 days, 
followed by 1 mg BID for 11 weeks.  The observational cohort study reported the majority but 
not entirety of subjects using the standardized dosing schedule.  For the RCTs, comparisons were 
made between varenicline and visually-matched placebo of identical dosage and schedule.  
Measured outcomes that are being utilized were neuropsychiatric adverse events (AEs) of a 
depressive type—including suicide attempt—and changes in depressive mood index. 
 Key words used in the searches were “varenicline,” “depression,” “randomized,” and 
“adverse.”  All articles were published in peer-reviewed journals and in the English language.  
The author searched the articles through PubMed and EBSCO, and selected articles based on 
relevance to the clinical question and inclusion of patient-oriented outcomes (suicide, depressive-
type AEs, or worsened index of depression).  Inclusion criteria consisted of studies where design 
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was either prospective or randomized, double-blind, placebo-controlled, studies that included 
patient-oriented outcomes, and studies of adult smokers > 18 years of age. Exclusion criteria 
consisted of studies with exclusively disease-oriented outcomes, studies that did not track 
adverse event data independent of efficacy data, and studies of smokers < 18 years of age.  The 
statistics reported in the studies included mean change from baseline, 95% confidence interval 
(CI), and p-value. 
OUTCOMES MEASURED 
 Outcomes measured were based on a psychiatric index of depression and incidence of 
reported AEs.  The index utilized was the Montgomery-Åsberg Depression Rating Scale 
(MADRS).12  The MADRS measures depressed mood using a 10-item list, with each item having 
a range of 0 (least severe) to 6 (most severe).  Each item assesses a different aspect of 
depression: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, 
concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts.  
AE reporting was coded and categorized based on the Medical Dictionary for Regulatory 
Activities version 12 and, in the observational cohort study, the British Drug Safety Research 
Unit standards. 
RESULTS 
 The two randomized, controlled trials in this review compared varenicline to placebo, and 
the observational cohort study compared varenicline within-subjects at 1-month intervals. 
 The study by Bollinger et al. was a randomized placebo-controlled study that included 593 
participants randomized into two intervention arms, of which 492 completed the study (83%). 
394 subjects were assigned to the varenicline arm, with 336 completing (85%), and 199 subjects 
were assigned to the placebo arm, with 156 completing (78%).  Duration of follow-up was 16  
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Table 1 - Demographics & Characteristics of included studies 
Study Type Pts. 
(n) 
Age Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions 
Bollinger 
et al. 
(2011) 2 
Double-
blind RCT 593 18–75 
y/o 
Adult smokers 
(18–75 y/o) 
with BMI 15–
38, weight of 
45.5+ kg, that 
smoked an 
average of 10+ 
cigarettes/day 
during the 
previous year 
and with no 
period of 
abstinence > 3 
months. 
Women of 
childbearing age that 
refused birth control 
methods during the 
study; any current or 
past history of 
psychiatric illness 
including present or 
past suicidal 
behavior, ideation or 
attempts; severe 
unstable medical 
condition; past 
history of varenicline 
use; concurrent use 
of smoking cessation 
medications; 
concurrent 
enrollment in other 
clinical trials 
101 Varenicline; 
dosage 
schedule: 0.5 
mg q.d. x 3 
days, then 0.5 
mg b.i.d. x 4 
days, then 1 mg 
b.i.d. x 11 
weeks 
Garza et 
al.  (2011) 
9 
Double-
blind RCT 110 18–75 
y/o 
Adult smokers 
(18–75 y/o) that 
smoked an 
average of 10+ 
cigarettes/day 
during the 
previous year 
and with no 
period of 
abstinence > 3 
months 
Women of 
childbearing age that 
refused birth control 
methods during the 
study; any current or 
past history of 
psychiatric illness 
including present or 
past suicidal 
behavior, ideation or 
attempts; severe 
unstable medical 
condition; past 
history of varenicline 
use; concurrent use 
of smoking cessation 
medications; 
concurrent 
enrollment in other 
clinical trials 
22 Varenicline; 
dosage 
schedule: 0.5 
mg q.d. x 3 
days, then 0.5 
mg b.i.d. x 4 
days, then 1 mg 
b.i.d. x 11 
weeks 
Kasliwal 
et al.  
(2009) 10 
Prospective 
cohort 
study 
2682 > 18 
y/o 
Adult smokers 
part of the 
English 
National Health 
Service (NHS) 
None 117 Varenicline; 
dosage 
schedules not 
consistently 
specified; 
73.6% of 
subjects clearly 
reported the 
standard 1 mg 
b.i.d. dosing 
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weeks, with adverse events (AEs) recorded up to 30 days after the administration of the last dose 
of the intervention. For purposes of this review, AEs were treated as the sum of AE categories 
“Depressed mood disorders or disturbances” and “Suicidal and self-injurious behaviors.”  No 
statistical significance in AE incidence was found between the varenicline and placebo groups (p 
> .05). Table 2 shows incidence of depressive AEs, where there was a small but nonsignificant 
difference of AE incidence in the varenicline group (36%) compared to the placebo group (35%). 
The relative risk increase (RRI) was calculated to be 57.1% and absolute risk increase (ARR) 
was 0.1%.  Numbers needed to harm (NNH) was calculated as 1,000, meaning 1,000 patients 
need to be treated with varenicline for 1 patient to suffer an additional depressive AE. 
Table 2: Incidence of depressive adverse events 
CER EER RRI ARI NNH P 
35% 36% 2.9% 0.1% 1,000 > .05 
 
 The study by Garza et al. was a randomized placebo-controlled study that included 110 
participants randomized into two intervention arms, of which 88 completed the study (80%). 55 
subjects were assigned to the varenicline arm, with 39 completing (71%), and 55 subjects were 
assigned to the placebo arm, with 49 completing (89%). Duration of follow-up was 16 weeks, 
with additional follow-up conducted for subjects categorized as “lost to follow-up” in the 
original study duration.  While a “worst-case” analysis was not done on all subjects lost to 
follow-up, the additional post-study follow-up determined that AEs accounted for only 3 of the 
16 subjects lost in the varenicline group.  Changes in depressive mood were measured by 
deviation from baseline MADRS scores for the varenicline group (LS mean ± SE: 1.52 ± .21) 
and placebo group (LS mean ± SE: 1.50 ≠ .28), as shown in table 3.  No significant difference 
was found between the two arms (difference = .03, 95% CI —.68–.73; p > .05).  For purposes of 
this review, adverse events were treated as the AE category “Depressed mood disorders or 
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disturbances;” no suicidal events were reported.  No significance in AE incidence was found 
between the varenicline and placebo groups (p > .05).  Table 4 shows incidence of depressive 
AEs, where there was a small but nonsignificant difference of AE incidence in the varenicline 
group (11%) compared to the placebo group (9.1%). The relative risk increase (RRI) was 
calculated to be 21% and absolute risk increase (ARI) was 1.9%. Numbers needed to harm was 
calculated as 52, meaning 52 patients need to be treated with varenicline for 1 patient to suffer an 
additional depressive AE. 
Table 3: Change from baseline MADRS total score (LS mean ± SE) 
Placebo Varenicline Difference P 
1.50 ± .28 1.52 ± .21 0.03 (95% CI —.68–.73) > .05 
 
 
Table 4: Incidence of depressive adverse events 
CER EER RRI ARI NNH P 
9.1% 11% 21% 1.9% 52 > .05 
   
 The study by Kasliwal et al. was the initial report of an ongoing observational cohort study 
of 2,682 patients in the British National Health Service (NHS).  While the study utilizes ongoing 
monthly questionnaires, the data reported represent the 4 months following the first prescription 
of varenicline for each given patient.  For the purposes of this review, 44 patients with a 
significant psychiatric past medical history (PMH) are excluded, and so the population of 
consideration is 2,638.  The 4-month incidence of depressive adverse events was 15 (0.57%), and 
of suicidal ideation was 1 (0.04%).  After accounting for the aforementioned exclusion, no 
suicidal events were reported.  Though the study was not designed or powered for between-
groups comparison, a recent study of overall depression rates within the NHS found a mean 4-
month incidence of combined depressive symptoms and depression diagnoses of 0.83%.14  While 
no protective effect of varenicline is presumed, the incidence of depression in the study’s 
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population was lower than the mean incidence of a larger NHS sample, as seen in table 5. 
 
Table 5: Incidence of depressive symptoms 
 Kasliwal et al. 10 
(n=2,638) 
Rait et al. 14 
(n=2,982,024) 
Difference 
Mean 4-month 
Incidence 
0.57% 0.83% —0.26% 
 
DISCUSSION 
 This literature review investigated the possibility that the use of varenicline for smoking 
cessation therapy might create or worsen depression in patients without known depressive 
illness.  The studies by Bollinger et al. and Garza et al. were randomized, controlled trials that 
failed to find a significant difference in new-onset depression between subjects taking 
varenicline and those taking placebo.  The study by Kasliwal et al. established reports of new-
onset depressive symptoms, but at a rate that was lower than an NHS mean for a similar time 
span. 
 Limitations were present in each study that affect their validity regarding the question of 
concern.  Kasliwal et al. utilized a large cohort size but by the observational nature of the study 
design, no significant causal links can be drawn between varenicline and depression.  Indeed, the 
results of that study might seem to indicate a protective effect of varenicline, but such a 
conclusion would be subject to significant sampling bias given the breadth of the NHS sample 
for depression incidence (e.g., the broader NHS data account for all patients in the sample 
population, not only those engaged in smoking-cessation therapy).  That study is further limited 
by the collection of data as reliant upon General Practitioner submission, adding both another 
possible sampling bias to the consideration and inconsistent/missing values from some 
questionnaires that “diluted” the overall data set. 
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 Both Bollinger et al. and Garza et al. acknowledged financial support by Pfizer, Inc., the 
U.S. marketer of the Chantix® brand of varenicline.  Bollinger et al. also acknowledged that 
their study was principally powered for efficacy analysis, limiting the extent of significance that 
could be established for adverse events reported.  Similarly, while the study by Garza et al. was 
specifically designed to assess neuropsychiatric AEs, its lack of a predefined hypothesis 
prevented the application of more rigorous statistical comparisons (e.g., t-test, ANOVA, 
ANCOVA).  Garza et al. also note that their study population was restricted to smokers willing 
and able to commit to a 2-week inpatient period, which raises the concern of sampling bias and 
reduced external validity. 
 Perhaps most importantly, no studies yet published—including those in this review—have 
adequately addressed two key points: 1) Smoking cessation itself is understood to be a possible 
aggravating factor in depression or suicide.11  If there is an increased link between varenicline 
and depression, is it a direct consequence of the drug’s pharmacology or a statistical 
consequence of the drug’s efficacy?  In other words, do more varenicline patients become 
depressed because more of them successfully quit smoking?  2) While new-onset depression is 
an undesirable POEM by itself, suicide is both a worse outcome and a rarer one.  Even in 
Kasliwal et al., a large sample size (n=2,682) yielded only 6 suicide-related events, of which 5 
were in patients with PMH significant for psychiatric illness.  Tracking such an outcome 
properly requires either a significant sample size or a series of RCTs—powered to assess suicide 
rate differences—that could be collapsed across a meta-analysis. 
CONCLUSION 
 The studies reviewed collectively are inconclusive regarding varenicline’s influence on 
new-onset depression.  While the lack of significance found in the comparisons by Garza et al. 
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and Bollinger et al. point toward a lack of causal link between varenicline and depression, 
limitations both in the design and implementation of those studies prevent that conclusion from 
being firmly supported.  Likewise, the study by Kasliwal et al. suffers limitations in design that, 
without strong evidence from either other study, hinder its use in conclusively proving or 
disproving a causal link between varenicline and new-onset depression. 
 More-substantial clinical research has established a link between varenicline and adverse 
neuropsychiatric outcomes other than depression, and varenicline continues to carry an FDA 
Black Box warning.13  Further, there is stronger evidence of a deleterious effect of varenicline 
when used by patients with existing depressive illness.  While this literature review indicates no 
significant association between varenicline and depressive events, it does not reliably rule out 
that such an association exists.  Cantrell et al. and others recommend that varenicline remain a 
second-line treatment option, and further suggest that some form of depression screening should 
be administered to all patients prior to varenicline use. 
 Ideally, future research into varenicline’s safety will focus on two points.  First, if there is 
a difference in depressive events with varenicline use, is it due directly to the drug’s 
neuropsychiatric effects or its improved quit rate?  Second, does careful screening and proactive 
mental health management improve outcomes for patients taking varenicline?  Until both 
questions are addressed with greater confidence, varenicline may have an uncertain role in 
modern smoking cessation therapy. 
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